Provided by Tiger Fintech (Singapore) Pte. Ltd.

Absci Corporation.

2.89
-0.6200-17.66%
Post-market: 2.940.0497+1.72%19:55 EDT
Volume:23.75M
Turnover:67.46M
Market Cap:416.16M
PE:-3.13
High:2.96
Open:2.93
Low:2.59
Close:3.51
Loading ...

Company Profile

Company Name:
Absci Corporation.
Exchange:
NASDAQ
Establishment Date:
2011
Employees:
157
Office Location:
18105 SE Mill Plain Boulevard,Vancouver,Washington,United States
Zip Code:
98683
Fax:
- -
Introduction:
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. It has a collaboration with Memorial Sloan Kettering Cancer Center to discover novel therapeutics using generative AI; with AstraZeneca PLC for AI-driven drug discovery against an oncology target; and with Twist Bioscience Corporation to design a novel therapeutic using generative AI. The company was founded in 2011 and is headquartered in Vancouver, Washington.

Directors

Name
Position
Frans Van Van Houten
Chairman of the Board
Sean McClain
Chief Executive Officer and Director
Daniel A. Rabinovitsj
Independent Director
Joseph Sirosh
Independent Director
Karen McGinnis
Independent Director
Professor Menelas Pangalos
Independent Director
Mary Szela
Director

Shareholders

Name
Position
Sean McClain
Chief Executive Officer and Director
Zachariah Jonasson
Chief Financial Officer and Chief Business Officer
Andreas Busch
Chief Innovation Officer
Shelby J. Walker
Chief Legal Officer
Todd Bedrick
Chief Accounting Officer